Trillium Therapeutics Inc. (Nasdaq: TRIL) stock has climbed 143% in 2015, and it's still one of the top biotech stocks to buy now.
You see, Trillium is at the forefront of a revolutionary treatment that could hold the key to curing various types of cancer.